Practical Solutions for Reducing Cerebral Infarction Recurrence
Study Overview
To reduce the risk of cerebral infarction recurrence after cerebrovascular intervention, a clinical trial was conducted on 202 patients. The treatment group received clopidogrel doublet augmented antiplatelet therapy, while the control group received aspirin mono-antiplatelet therapy. Both groups continued the treatment for 2 months.
Key Findings
After treatment, patients in the treatment group showed lower levels of platelet activation, inflammatory factors, and NIHSS score compared to the control group. Additionally, the recurrence of cerebral infarction within 6 months after treatment was lower in the treatment group compared to the control group.
Implications
The study suggests that dual-enhanced antiplatelet therapy may be effective in reducing the risk of cerebral infarction recurrence after cerebrovascular intervention. However, the effectiveness of the therapy is influenced by various factors such as smoking history, vascular plaque, and genetic polymorphism.
Value of AI-Driven Platform in Healthcare
Clinical trials play a crucial role in developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards, protocols, and research into a single, easily accessible knowledge base for clinicians, helping to extend the benefits of clinical trials into everyday medical practice.
Streamlining Healthcare Operations with Mobile Apps
In today’s healthcare environment, streamlining operations is essential. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
Enhancing Workflows with AI
By utilizing AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routines. Learn more about how we can help at aidevmd.com.
